Abstract
Purpose: To validate preoperative C-reactive protein (CRP) levels as a prognostic marker for survival in a metastasized renal cell carcinoma (mRCC) patient cohort receiving cytoreductive nephrectomy (CN). Patients and Methods: By chart review, 146 mRCC patients receiving CN at our tertiary referral centre from 1997 to 2015 were identified retrospectively. All relevant clinicopathological features including laboratory parameters were collected and correlated to overall survival, progression-free survival and cancer-specific survival (CSS). The mean follow-up was 23 months (range 1-168 months). Results: Besides the already established scoring systems like the MSKCC criteria, an elevated preoperative CRP level (≥0.5 mg/dL) was an independent predictor of CSS in our study group including the chosen postoperative adjuvant therapies (TKI vs. immunotherapy vs. others). With regard to morbidity, patients with a good performance status, small tumour size and adequate renal function/haematopoiesis experienced less complication rates, thereby profiting more from CN. Conclusions: Our data provide indication that preoperative CRP levels should be implemented in nomograms regarding the outcome prediction in mRCC to identify candidates likely to profit from CN.
References
1.
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2.
McKiernan J, Wood CG: Cytoreductive nephrectomy for metastatic renal cell carcinoma. J Urol 2013;190:386-388.
3.
Gershman B, Moreira DM, Boorjian SA, Lohse CM, Cheville JC, Costello BA, et al: Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol 2016;69:84-91.
4.
Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard J, et al: Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol 2015;33:339.e9-e15.
5.
Heng DY, Wells JC, Rini BI, et al: Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur Urol 2014;66:704-710.
6.
Noe A, de Bruijn RE, Blank C, Horenblas S, Haanen J, Bex A: Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J Urol 2016;34:1067-1072.
7.
Atzpodien J, Royston P, Wandert T, Reitz M: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003;88:348-353.
8.
Ito H, Shioi K, Murakami T, Takizawa A, Sano F, Kawahara T, et al: C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy. BMC Cancer 2012;12:337.
9.
Sakai I, Miyake H, Hinata N, Fujisawa M: Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol 2014;19:674-678.
10.
Kamba T, Yamasaki T, Teramukai S, Shibasaki N, Arakaki R, Sakamoto H, et al: Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice. Int J Clin Oncol 2014;19:505-515.
11.
Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K: Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol 2008;180:515-519.
12.
Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, Kihara K: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 2009;55:1145-1154.
13.
Teishima J, Kobatake K, Hayashi T, Seno Y, Ikeda K, Nagamatsu H, et al: Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncol Letters 2014;8:881-885.
14.
Fujita T, Nishi M, Tabata KI, Matsumoto K, Yoshida K, Iwamura M: Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib. Anticancer Drugs 2016;27:1028-1032.
15.
Teishima J, Kobatake K, Kitano H, Nagamatsu H, Sadahide K, Hieda K, et al: The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma. BJU Int 2015;117:E67-E74.
16.
Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, et al: Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int 2014;114:81-89.
17.
Reichle A, Grassinger J, Bross K, Wilke J, Suedhoff T, Walter B, et al: C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation. Biomarker Insights 2006;1:87.
18.
Jabs WJ, Busse M, Krüger S, Jocham D, Steinhoff J, Doehn C: Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005;68:2103-2110.
19.
Zhang HX, Chen ZQ, Ye ZQ: Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2014;15:3369-3375.
20.
Zhou L, Cai X, Liu Q, Jian ZY, Li H, Wang KJ: Prognostic role of C-reactive protein in urological cancers: a meta-analysis. Sci Rep 2015;5:12733.
21.
Hu Q, Gou Y, Sun C, Ding W, Xu K, Gu B, Ding Q: The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 2014;32:50.e1-e8.
22.
Johnson TV, Abbasi A, Owen-Smith A, Young AN, Kucuk O, Harris WB, et al: Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 2010;76:766.e1.
23.
Ohno Y, Nakashima J, Ohori M, Tanaka A, Hashimoto T, Gondo T, et al: Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol 2014;19:139-145.
24.
Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG: Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:3378-3388.
25.
You D, Jeong IG, Song C, Lee JL, Hong B, Hong JH, et al: Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Jpn J Clin Oncol 45:96-102.
26.
Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, et al: Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 2013;63:947-952.
27.
Rausch S, Kruck S, Walter K, Stenzl A, Bedke J: Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C-reactive protein is an independent predictor of overall survival. Int J Urol 2016;23:916-921.
28.
Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006;13:1365-1370.
29.
Kim SH, Kim S, Joo J, Seo HK, Joung JY, Lee KH, Chung J: A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy. BMC Cancer 2016;16:577.
30.
Jagdev SPK, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, et al: Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010;103:1649-1656.
31.
Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, et al: Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer 2012;107:1131-1137.
32.
Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, et al: Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 2012;12:1.
33.
Chen Z, Shao Y, Fan M, Zhuang Q, Wang K, Cao W, He X: Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol 2015;8:14893.
34.
Xia WK, Wu X, Yu TH, Wu Y, Yao XJ, Hu H: Prognostic significance of lymphocyte-to-monocyte ratio and CRP in patients with nonmetastatic clear cell renal cell carcinoma: a retrospective multicenter analysis. Onco Targets Ther 2016;9:2759-2767.
35.
Hamidi N, Gökçe MI, Süer E, Baltaci S: Evaluation of increased preoperative serum high sensitive C-reactive protein and procalcitonin levels on grade and stage of clear cell renal cell carcinoma. Clin Nephrol 2015;83:225-230.
36.
Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, et al: Inflammatory prognostic markers in clear cell renal cell carcinoma-preoperative C-reactive protein does not improve predictive accuracy. BJU Int 2012;110(11 pt B):E771-E777.
37.
Kim SP, Murad MH, Thompson RH, Boorjian SA, Weight CJ, Han LC: Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012;188:51-57.
38.
Kalogirou C, Fender H, Muck P, Hey V, Krebs M, Riedmiller H, Vergho D: Long-term outcome of nephron-sparing surgery compared to radical nephrectomy for renal cell carcinoma? 4 cmA matched-pair single institution analysis. Urol Int 2016;98:138-147.
39.
Dirican A, Kucukzeybek Y, Somali I, Erten C, Demir L, Can A, Alacacioglu A: The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma. J BUON 2012;18:413-419.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
